DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Balar AV, Kulkarni GS, Uchio EM, Boormans J, Moure L, Krieger LEM. et al
Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG).
J Clin Oncol 2019;
37: 350
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.